• VolitionRx reduced CEO Cameron Reynolds’ annual base salary to $236,970.50 from $355,456, effective November 1, 2026.
• The November 10, 2026, agreement extends temporary salary cuts under cost-reduction measures, without additional equity compensation.
• The compensation committee may restore salary wholly or partly when financial stability improves; any reinstatement will not apply retroactively.
• Termination-related payments and pension allowances remain based on Reynolds’ full contractual annual base salary of $473,941.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-26-006845), on November 12, 2026, and is solely responsible for the information contained therein.